Using value of information analysis to prioritise health research: some lessons from recent UK experience - PubMed (original) (raw)

Review

Using value of information analysis to prioritise health research: some lessons from recent UK experience

Karl P Claxton et al. Pharmacoeconomics. 2006.

Abstract

Decisions to adopt, reimburse or issue guidance on the use of health technologies are increasingly being informed by explicit cost-effectiveness analyses of the alternative interventions. Healthcare systems also invest heavily in research and development to support these decisions. However, the increasing transparency of adoption and reimbursement decisions, based on formal analysis, contrasts sharply with research prioritisation and commissioning. This is despite the fact that formal measures of the value of evidence generated by research are readily available. The results of two recent opportunities to apply value of information analysis to directly inform policy decisions about research priorities in the UK are presented. These include a pilot study for the UK National Co-ordinating Centre for Health Technology Assessment (NCCHTA) and a pilot study for the National Institute for Health and Clinical Excellence (NICE). We demonstrate how these results can be used to address a series of policy questions, including: is further research required to support the use of a technology and, if so, what type of research would be most valuable? We also show how the results can be used to address other questions such as, which patient subgroups should be included in subsequent research, which comparators and endpoints should be included, and what length of follow up would be most valuable.

PubMed Disclaimer

Similar articles

• Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
  Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman E, Youn J. Claxton K, et al. Health Technol Assess. 2012;16(46):1-323. doi: 10.3310/hta16460. Health Technol Assess. 2012. PMID: 23177626
• Using value of information analysis to inform publicly funded research priorities.
  Ginnelly L, Claxton K, Sculpher MJ, Golder S. Ginnelly L, et al. Appl Health Econ Health Policy. 2005;4(1):37-46. doi: 10.2165/00148365-200504010-00006. Appl Health Econ Health Policy. 2005. PMID: 16076237
• The use of economic evaluations in NHS decision-making: a review and empirical investigation.
  Williams I, McIver S, Moore D, Bryan S. Williams I, et al. Health Technol Assess. 2008 Apr;12(7):iii, ix-x, 1-175. doi: 10.3310/hta12070. Health Technol Assess. 2008. PMID: 18373906
• An assessment of the impact of the NHS Health Technology Assessment Programme.
  Hanney S, Buxton M, Green C, Coulson D, Raftery J. Hanney S, et al. Health Technol Assess. 2007 Dec;11(53):iii-iv, ix-xi, 1-180. doi: 10.3310/hta11530. Health Technol Assess. 2007. PMID: 18031652 Review.
• Economic evaluation and decision making in the UK.
  Buxton MJ. Buxton MJ. Pharmacoeconomics. 2006;24(11):1133-42. doi: 10.2165/00019053-200624110-00009. Pharmacoeconomics. 2006. PMID: 17067197 Review.

Cited by

• Model-based economic evaluation for medical decision making: learn from the past and prepare for the future.
  Xie F. Xie F. J Thorac Dis. 2013 Jun;5(3):209-10. doi: 10.3978/j.issn.2072-1439.2013.05.04. J Thorac Dis. 2013. PMID: 23825746 Free PMC article. No abstract available.
• Estimating development cost of an interactive website based cancer screening promotion program.
  Lairson DR, Chung TH, Smith LG, Springston JK, Champion VL. Lairson DR, et al. Eval Program Plann. 2015 Jun;50:56-62. doi: 10.1016/j.evalprogplan.2015.01.009. Epub 2015 Feb 23. Eval Program Plann. 2015. PMID: 25749548 Free PMC article.
• Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
  McCullagh L, Walsh C, Barry M. McCullagh L, et al. Pharmacoeconomics. 2012 Oct 1;30(10):941-59. doi: 10.2165/11591510-000000000-00000. Pharmacoeconomics. 2012. PMID: 22667458
• Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions?
  Sculpher MJ, Drummond MF. Sculpher MJ, et al. Pharmacoeconomics. 2006;24(11):1087-99. doi: 10.2165/00019053-200624110-00006. Pharmacoeconomics. 2006. PMID: 17067194 Review.
• Use of a decision-analytic model in a health technology assessment: beyond measuring value for money.
  Kim SY. Kim SY. Isr J Health Policy Res. 2013 Apr 22;2(1):15. doi: 10.1186/2045-4015-2-15. Isr J Health Policy Res. 2013. PMID: 23607625 Free PMC article.

References

1. 1. Health Econ. 2005 Apr;14(4):339-47 - PubMed
2. 1. N Engl J Med. 1999 Jun 17;340(24):1881-7 - PubMed
3. 1. Lancet. 2002 Aug 31;360(9334):711-5 - PubMed
4. 1. Med Decis Making. 2004 Mar-Apr;24(2):207-27 - PubMed
5. 1. JAMA. 2001 Feb 7;285(5):535-9 - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer